Clinical Trial: SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214818) titled 'SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome' on Oct. 06.

Brief Summary: This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone.

The primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, ser...